

A retrospective analysis of gene fusions and treatment outcomes in pediatric acute megakaryoblastic leukemia without Down syndrome

Authors

Kyogo Suzuki,¹ Asahito Hama,¹ Yusuke Okuno,² Yinyan Xu,¹ Atsushi Narita,¹ Nao Yoshida,³ Hideki Muramatsu,¹ Nobuhiro Nishio,⁴ Koji Kato,³ Seiji Kojima,¹ Keon Hee Yoo^{5#} and Yoshiyuki Takahashi[#]

¹Department of Pediatrics, Nagoya University Graduate School of Medicine, Aichi, Japan; ²Department of Virology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan; ³Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Aichi, Japan; ⁴Department of Advanced Medicine, Nagoya University Hospital, Aichi, Japan and ⁵Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

#KHY and YT contributed equally as senior authors.

Correspondence:

Y. TAKAHASHI - ytakaha@med.nagoya-u.ac.jp

K.H. YOO - hema2170@skku.edu

<https://doi.org/10.3324/haematol.2023.283760>

Supplementary Material

Supplementary Tables pp. 2–3

Table S1. Primer sets for reverse transcription-polymerase chain reaction.

Table S2. Key clinical information of the patients.

Supplementary Tables

Table S1. Primer sets for reverse transcription-polymerase chain reaction.

Target	Forward (F) / Reverse (R)	Primer sequences (from 5' to 3')
<i>KMT2A</i> [†]	F	CGTCGAGGAAAAGAGTGA
:: <i>MLLT3</i>	R	ATGTTTCCAGGTAACCTCTGTAGT
:: <i>MLLT10</i>	R	CTGGAAATTTGCATTTGTAA
:: <i>MLLT1</i>	R	TACCCCGACTCCTCTACTT
:: <i>ELL</i>	R	CCCATGACTGGAGACATACT
<i>CBFA2T3</i> :: <i>GLIS2</i>	F1	CATCTGGAGGAAGGCTGA
	R1	CGGTTGTGGATCTTCAGGT
	F2	TCGGGAAAGGCAGTCCTGGTAGA
	R2	CACAGAAGAGTTTCCGTTTCGTCGG
<i>NUP98</i> :: <i>KDM5A</i>	F1	AGGGCCTCTTGGTACAG
	R1	TAGCTTCCGTTTCCGTTTCT
	F2	GTAACCCAGCACCTGGGACTCTTGG
	R2	GCCCCTGCTTCTTTGCACAGTTTAT
<i>RBM15</i> :: <i>MRTFA</i>	F1	CAAAGACAAGGAAAACACCGG
	R1	TCCAAAATGTGCATCCTGACC
	F2	ATGCCTTCCCACCTTGTGAG
	R2	CGCTCCAAGCTCCTTCTCTG
<i>FUS</i> :: <i>ERG</i>	F	CAGAGCTCCCAATCGTCTTACGG
	R	CAGGAGCTCCAGGAGGAACTGC
<i>MN1</i> :: <i>FLI1</i>	F	CGGCCTGGGCATCATGTCTAAC
	R	ACTGATCGTTTGTGCCCTCCA
<i>GATA2</i> :: <i>HOXA2</i>	F	TGACGGAGAGCATGAAGATGGAAAG
	R	GAAGGGGACGGACAGTTCTTTCTT
<i>NIPBL</i> :: <i>HOXB9</i>	F	CCATGCACAGTAGTCCTGCATCTTCC
	R	TAGAACCCGGGCTTGCCTGACA
<i>C8orf76</i> :: <i>HOXA11AS</i>	F	CTCTGCGAGCCGCAGTGGTTTT
	R	GCGCCGGCCTCTTCAAGAAATG

[†]The *KMT2A* forward primer was shared between every reaction for *KMT2A* rearrangements.

Table S2. Key clinical information of the patients.

	Total, <i>n</i> = 30	
<i>Age at diagnosis, median, years</i>	1.3	(IQR, 0.3–1.8)
<i>Sex, n</i>		
Male	14	(47%)
Female	16	(53%)
<i>WBC count, median, × 10⁹ /L</i>	12.7	(IQR, 6.0–18.7)
<i>Blast count in blood, median, × 10⁹ /L</i>	1.3	(IQR, 0.3–4.4)
<i>Hemoglobin, median, g/L</i>	82	(IQR, 68–88)
<i>Platelet count, median, × 10⁹ /L</i>	37.5	(IQR, 20.8–61.3)
<i>Serum LDH, median, IU/L</i>	1,513	(IQR, 577–3,153)
<i>Hepatomegaly, n</i>	21	(70%)
<i>Splenomegaly, n</i>	16	(53%)
<i>Hematopoietic cell transplantation, n</i>	18	(60%)
<i>Follow-up period, median, months</i>	91	(IQR, 12–145)
<i>Status at the final follow-up, n</i>		
Alive	20	(67%)
Dead	10	(33%)

Abbreviations; IQR, interquartile range; LDH, lactate dehydrogenase; WBC, white blood cell.